Clinical Trial Update: NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating NT-I7 (efineptakin alfa), a long-acting IL-7, in patients with relapsed/refractory diffuse large B-cell lymphoma after CAR-T therapy (a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• NT-I7

Snippet

Sponsor: Washington University School of Medicine | Conditions: Large B-cell Lymphoma | Phase 1 | Status: RECRUITING